FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Date/App# patent app List of recent Receptor-related patents
04/23/15
20150112067
 Process for making cgrp receptor antagonists patent thumbnailnew patent Process for making cgrp receptor antagonists
The disclosure encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, having less steps and improved yields as compared to previous synthetic methods for making these compounds, which are cgrp receptor antagonists, useful for the treatment of migraine. Conditions for an amide bond formation between an acid and amine include for example reacting the compounds of formulae b (after salt break) and c with an amide coupling reagent and optionally an additive and an acid and/or a base in a non-reactive solvent..
Merck Sharp & Dohme
04/23/15
20150111933
 Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor patent thumbnailnew patent Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor
The present invention relates to deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor and their use for treating fertility disorders.. .
Merck Patent Gmbh
04/23/15
20150111926
 Synergistic pesticidal compositions and related methods patent thumbnailnew patent Synergistic pesticidal compositions and related methods
A pesticidal composition comprises a synergistically effective amount of an ecdysone receptor agonist compound and a pesticide selected from n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (i), n-(3-chloro-1-(pyridine-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl)propanamide (ii), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
Dow Agrosciences Llc
04/23/15
20150111920
 Selective ep4 receptor antagonistic substance for treatment of cancer patent thumbnailnew patent Selective ep4 receptor antagonistic substance for treatment of cancer
This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin e2 receptor (ep4 receptor) and is represented by the following general formula (i), (ii), (iii), or (iv), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer.
Raqualia Pharma Inc.
04/23/15
20150111914
 Spirolactam cgrp receptor antagonists patent thumbnailnew patent Spirolactam cgrp receptor antagonists
The present invention is directed to spirolactam analogues which are antagonists of cgrp receptors and useful in the treatment or prevention of diseases in which cgrp is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.
04/23/15
20150111908
 Methods of diagnosing, preventing, and treating bone mass diseases patent thumbnailnew patent Methods of diagnosing, preventing, and treating bone mass diseases
The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are tph1 inhibitors or serotonin receptor antagonists..
04/23/15
20150111903
 Pharmaceutical formulations comprising neurotrophin mimetics patent thumbnailnew patent Pharmaceutical formulations comprising neurotrophin mimetics
Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75ntr receptor molecule.
U.s. Government Represented By The Department Of Veterans Affairs
04/23/15
20150111895
 Substituted triazolo-pyridazine derivatives patent thumbnailnew patent Substituted triazolo-pyridazine derivatives
This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-gaba-a receptor antagonist and/or a α2, α3 and α5 gaba-a receptor agonist..
Concert Pharmaceuticals Inc.
04/23/15
20150111889
 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists patent thumbnailnew patent Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists
The present invention relates to compounds of the formula (i), wherein the residues a, r1 to r5, z1 and z2 have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi
04/23/15
20150111886
 Novel adamantyl derivatives as cannabinoid receptor 2 agonists patent thumbnailnew patent Novel adamantyl derivatives as cannabinoid receptor 2 agonists
Wherein a1, r1 and r2 are defined as in the description and in the claims. The compound of formula (i) can be used as a medicament..
04/23/15
20150111826
new patent

Acylated glucagon analogues


The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Boehringer Ingelheim International Gmbh
04/23/15
20150111817
new patent

Glucagon analogues


The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods.
Boehringer Ingelheim International Gmbh
04/23/15
20150111816
new patent

Methods and treatment with glp-1 receptor agonists


The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a glp-1 receptor agonist, or a regimen of glp-1 receptor agonist comprising a plurality of substantially evenly spaced doses.
Phasebio Pharmaceuticals, Inc.
04/23/15
20150111743
new patent

Synergistic pesticidal compositions and related methods


A pesticidal composition comprises a synergistically effective amount of a nicotinic acetylcholine receptor (nachr) allosteric activator compound and a pesticide selected from n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)thio) propanamide (i), n-(3-chloro-1-(pyridine-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl) propanamide (ii), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
Dow Agrosciences Llc
04/23/15
20150111741
new patent

Synergistic pesticidal compositions and related methods


A pesticidal composition comprises a synergistically effective amount of a nicotinic acetylcholine receptor (nachr) agonist compound and a pesticide selected from n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (i), n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl)propanamide (ii), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
Dow Agrosciences Llc
04/23/15
20150111740
new patent

Synergistic pesticidal compositions and related methods


A pesticidal composition comprises a synergistically effective amount of a sulfoximine-based nicotinic acetylcholine receptor (nachr) agonist compound and a pesticide selected from n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)thio) propanamide (i), n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl) sulfinyl) propanamide (ii), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
Dow Agrosciences Llc
04/23/15
20150111736
new patent

Synergistic pesticidal compositions and related methods


A pesticidal composition comprises a synergistically effective amount of a ryanodine receptor modulator compound and a pesticide selected from n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (i), n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-n-ethyl-3-(((3,3,3-trifluoropropyl)sulfinyl)propanamide (ii), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
Dow Agrosciences Llc
04/23/15
20150111294
new patent

Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters


Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and cd40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible cd40 peptide and an inducible pattern recognition receptor adapter or adapter fragment..
Bellicum Pharmaceuticals, Inc.
04/23/15
20150111229
new patent

Method for searching for inhibitor of odor cause by furaneol


It is intended to identify a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2h)-furanone. The present invention provides a method for searching for an inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2h)-furanone, comprising: adding a test substance and 2,5-dimethyl-4-hydroxy-3(2h)-furanone to an olfactory receptor or5k1 or a polypeptide having at least 80% amino acid sequence identity thereto; measuring the response of the olfactory receptor or the polypeptide to 2,5-dimethyl-4-hydroxy-3(2h)-furanone; and identifying a test substance inhibiting the response of the olfactory receptor or the polypeptide, on the basis of the measured response..
Kao Corporation
04/23/15
20150111137
new patent

Cross-linked overcoat layer


Embodiments pertain to a novel imaging member, namely, an imaging member or photoreceptor comprising an overcoat layer which comprises a soluble filler that improves low surface energy and wear. The soluble filler is a silicone poly(ethylene glycol) ester which improves low surface energy and wear without negatively impacting electrical properties of the overcoat layer..
Xerox Corporation
04/23/15
20150110865
new patent

Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment


Combinations comprise a therapeutically effective amount of one or more stimulants and and/or pharmaceutically acceptable analogs, salts, or hydrates of the one or more stimulants, and one or more non-selective opioid receptor antagonists, and/or pharmaceutically acceptable analogs, salts or hydrates of the one or more non-selective opioid receptor antagonists. These combinations may be used for treating obesity via administration to a subject having a need thereof..
The General Hospital Corporation
04/23/15
20150110861
new patent

Compositions and methods for sirna inhibition of angiogenesis


Rna interference using small interfering rnas which are specific for the vascular endothelial growth factor (vegf) gene and the vegf receptor genes flt-1 and flk-1/kdr inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of vegf, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering rnas..
The Trustees Of The University Of Pennsylvania
04/23/15
20150110832
new patent

Deletion mutants of flagellin and methods of use


Compositions that include toll-like receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection..
Vaxinnate Corporation
04/23/15
20150110816
new patent

Methods of treatment using anti-erbb antibody-maytansinoid conjugates


The application concerns methods of treatment using anti-erbb receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns erbb receptor-directed cancer therapies, using anti-erbb receptor antibody-maytansinoid conjugates..
Immunogen Inc.
04/23/15
20150110812
new patent

Production of her receptor antibodies in plant


A method of making an antibody in plants that binds to a her receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants..
04/23/15
20150110811
new patent

Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers


This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of toll-like receptor 4 (tlr4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of tlr4 ligands and other biomarkers using agents that interfere with or otherwise antagonize tlr4 signaling, including neutralizing anti-tlr4 antibodies..
Novimmune S.a.
04/23/15
20150110807
new patent

Hdc-sign binding peptides


Polypeptides that bind to dc-sign and/or its homologues and methods for using such peptides for the treatment of various disorders are described. Dc-sign and its homologues are receptors that bind igg antibodies or fc fragments and mediate intravenous immunoglobulin (ivig)-related reversal of inflammation associated with various immune disorders..
Sloan-kettering Institute For Cancer Research
04/23/15
20150110806
new patent

Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia


The present invention concerns the use of an inhibitor of an interaction between type iv pilus-associated protein and cd147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection.
Universite Paris Descartes
04/23/15
20150110800
new patent

Use of semaphorin-4d binding molecules for treating neurodegenerative disorders


Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4d (sema4d) or to its plexin-b1 or plexin-b2 receptors.. .
Vaccinex, Inc.
04/23/15
20150110798
new patent

Anti-human folate receptor beta antibodies and methods of use


Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface frβ.. .
The United States Of America, As Represented By The Secretary Department Of Health And Human Servi
04/23/15
20150110791
new patent

Anti-transferrin receptor antibodies and methods of use


The present invention relates to anti-transferrin receptor antibodies and methods of their use.. .
Genentech, Inc.
04/23/15
20150110782
new patent

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor


The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to tumor necrosis factor-alpha. It further relates to single domain antibodies that are camelidae vhhs.
Ablynx N.v.
04/23/15
20150110760
new patent

Nkp30 receptor targeted therapeutics


The invention is directed to t cells and other cells that express chimeric nk-p30 receptors (“chimeric nkp30 t cells”), methods of making and using chimeric nkp30 t cells, and methods of using these chimeric nkp30 t cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric nkp30 t cells are further designed to express a functional non-tcr receptor.
Trustees Of Dartmouth College
04/23/15
20150110742
new patent

Tlr-agonist-conjugated antibody recruiting molecules (tlr-arms)


The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (abt) moiety covalently bonded to a cell binding terminus (cbt) and toll-like receptor agonist (tlr) through a linker and a multifunctional connector group or molecule..
Yale University
04/23/15
20150110739
new patent

Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration


The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (il-12) receptor. The present application also provides methods for making and for using the stem cells..
Neumedicines, Inc.
04/23/15
20150110731
new patent

Inhibitor of odor caused by furaneol


Provided is a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2h)-furanone. An inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2h)-furanone, comprising a substance inhibiting the response of an olfactory receptor or5k1 as an active ingredient..
Kao Corporation
04/23/15
20150110669
new patent

Inhibitor of odor caused by sotolone


It is intended to provide a substance inhibiting an odor caused by sotolone. The present invention provides an inhibitor of an odor caused by sotolone, comprising an antagonist of an olfactory receptor or8d1 as an active ingredient..
Kao Corporation
04/23/15
20150109607
new patent

Multi point, high sensitive tactile sensing module for robots and devices


The features of the system are: fiber optic cables (instead of human sensory receptor) and low cost cmos or ccd image sensor (which can be found in a conventional webcam, camcorder, digital camera etc.) are used by pairing each pixel of the image sensor with corresponding fiber optic cable, which is assured to transfer all light beams to the processor on a single photo frame where the coordinates and the level of displacements are detected precisely by the aid of image processing techniques, in order to provide tactile sensing. The system can work with a computer or it can work individually with an electronically circuit that contains an independent processor..
04/16/15
20150105864

Biocompatible implants and methods of making and attaching the same


The invention provides a biocompatible silicone implant that can be securely affixed to living tissue through interaction with integral membrane proteins (integrins). A silicone article containing a laser-activated surface is utilized to make the implant.
Doheny Eye Institute
04/16/15
20150105844

Device and stimulation by means of thermal stimuli


The invention relates to a device for the stimulation of thermal receptors in the skin of a patient by means of thermal stimuli. The device comprises a plurality of noninvasive stimulation units for irradiating the skin of the patient with electromagnetic radiation, wherein thermal stimuli are produced by absorption of the electromagnetic radiation in the skin of the patient and the wavelength range of the electromagnetic radiation emitted by the stimulation units can be adjusted.
Forschungszentrum Juelich Gmbh
04/16/15
20150105712

Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same


Iontophoretic devices for transdermal delivery of a sphingosine-1-phosphate receptor agonist active agent are provided. Also provided are methods of transdermally delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat immune system disorders such as multiple sclerosis.
Teikoku Pharma Usa, Inc.
04/16/15
20150105462

Compositions and methods for topical delivery of prostaglandins to subcutaneous fat


Described herein are compositions comprising a prostaglandin fp receptor agonist (pfpra) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the pfpra compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin.
Topokine Therapeutics, Inc.
04/16/15
20150105428

Compositions and methods for modulating circadian synchronization


The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag.
Max-planck-gesellschaft-zur-förderung Der Wissenschaften E.v.
04/16/15
20150105421

Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide


The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (cns).. .
Targacept, Inc.
04/16/15
20150105416

Treating postoperative nausea and vomiting


Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (ponv) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia.
04/16/15
20150105403

Estrogen receptor modulators and uses thereof


Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..
Seragon Pharmaceuticals, Inc.
04/16/15
20150105396

Chemical compounds


And pharmaceutically acceptable salts thereof, wherein r1, r2, r3, r4 and r5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the gabaa receptor.
04/16/15
20150105392

Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents


Wherein: ar, z, r3, r4 and r5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.
04/16/15
20150105381

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors


The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (i), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.. .
Domain Therapeutics
04/16/15
20150105371

Co-crystals and salts of ccr3-inhibitors


Pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the ccr3-receptor.. .
04/16/15
20150105370

Selectively substituted quinoline compounds


Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis.. .
Eisai R&d Management Co., Ltd.
04/16/15
20150105364

Nmda receptor modulators and uses thereof


Disclosed are compounds having enhanced potency in the modulation of nmda receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.
Northwestern University
04/16/15
20150105360

Therapeutic compositions and method


This invention relates the use of cortisol blockers (glucocorticoid receptor [gr] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc.
Pop Test Cortisol Llc
04/16/15
20150105349

(r)-(-)-1,2-propanediol compositions and methods


Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor.
04/16/15
20150105334

Peptides derived from nkp44


The invention provides specific peptides derived from the cytotoxicity receptor nkp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of nkp44 for preventing or treating cancer..
Ben-gurion University Of The Negev
04/16/15
20150105332

Somatostatin receptor agonist formulations


The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt.
Camurus Ab
04/16/15
20150105294

Piezoelectric microcantilever sensors for biosensing


A piezoelectric microcantilever for sensing compounds or molecules. The piezoelectric microcantilever, may include at least one electrode, an insulation layer, a receptor, an immobilization layer, a non-piezoelectric layer and a piezoelectric layer the sensor is capable of self actuation and detection.
Drexel University
04/16/15
20150105288

Genetically modified non-human animals and methods relating to innate immune system response detection


Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (tlr4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (tlr4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells..
University Of Massachusetts
04/16/15
20150104866

Ip-10 antibodies and their uses


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.
04/16/15
20150104831

Antibodies and uses thereof


The present invention provides antibodies which bind to an epitope in the extracellular domain of human cc chemokine receptor 4 (ccr4) and which are capable of inhibiting the binding of macrophage-derived chemokine (mdc) and/or thymus and activation regulated chemokine (tarc) to ccr4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields..
Affitech Research As
04/16/15
20150104587

Nanofluidic sensor comprising spatially separated functional sensing components


A method for making multiple single molecule receptors in a nanopore structure includes depositing a first material and a second material by a physical vapor deposition (pvd) technique onto different selected interior surfaces of a nanochannel and functionalizing a surface of the first material, the second material, or both the first and second materials with a chemical compound having at least two functional groups. The first and second materials can be the same or different and form patches having diameters of about 1 to about 100 nanometers (nm).
International Business Machines Corporation
04/16/15
20150104586

Directed surface functionalization on selected surface areas of topographical features with nanometer resolution


A method for making a single molecule receptor in a nanopore structure includes depositing a material by a physical vapor deposition (pvd) technique onto a selected interior surface of a nanochannel and functionalizing a surface of the material with a chemical compound having at least two functional groups. The material forms a patch having a diameter of about 3 to about 10,000 nanometers (nm).
International Business Machines Corporation
04/16/15
20150104506

Orally available pharmaceutical formulation suitable for improved management of movement disorders


The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-ht1b, 5-ht1d and 5-ht1f receptors, such as a triptan, e.g. Zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-ht1a-r agonist, such as buspirone, in a constituent with immediate-release characteristics.
Contera Pharma Aps
04/16/15
20150104497

Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same


Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer.
Teikoku Pharma Usa, Inc.
04/16/15
20150104482

Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing


Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (tlr7) ligand activity, 2) an immunostimulatory k-type cpg oligodeoxynucleotide (odn) comprising an unmethylated cpg motif, 3) an antibiotic, and 4) a surfactant, wherein the composition is formulated for topical administration.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
04/16/15
20150104462

Use of semaphorin-4d binding molecules for treatment of atherosclerosis


Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4d (sema4d) or to its high affinity plexin-b1 receptor.. .
Vaccinex, Inc.
04/16/15
20150104458

House dust mite allergen


A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence seq id no. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence seq id no.
Biomay Ag
04/16/15
20150104441

Identification of disease-driving antigens


Provided herein is technology relating to treating disease and particularly, but not exclusively, to methods for identifying disease-related antigens by assessing t cell receptor gene frequencies in diseased subjects.. .
Oslo Universitetssykehus Hf
04/16/15
20150104440

Mirna-31 as a diagnostic, prognostic and therapeutic agent in cancer


The current disclosure reveals a complex regulatory pattern between mir-31 and ar, indicating that mir-31 plays a key role in prostate cancer development and progression. Another aspect of the current disclosure shows that mir-31 directly targets and destabilizes ar mrna through interaction with the ar mrna coding sequence showing that mir-31, or a fragment thereof has the ability to act as a novel therapeutic agent in treating cancer.
Cornell University
04/16/15
20150104429

Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression


Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with an effective amount of a synthetic triterpenoid to induce the expression of one or more of sox9 (sex determining region y-box 9), col2a1 (type ii collagen (alpha1)), tgf-βi, tgf-p2, tgf-33, bmp2, bmp4, bmprii (bone morphogenic protein receptor ii), smad (small mothers against decapentaplegic) 3, smad4, smad6, smad7, timp (tissue inhibitor of metalloproteinase)-1 or timp-2 in the stem or progenitor cell, wherein the stem or progenitor cell is not a mesenchymal stem cell, periosteium cell or osteoprogenitor cell.
Trustees Of Dartmouth College
04/16/15
20150104388

Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use


This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (pacap), which are agonists for the pacap/vasoactive intestinal peptide (vip) receptors: pac1, vpac1 and vpac2 receptors. These pacap analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease.
The Administrators Of The Tulane Educational Fund
04/16/15
20150104385

Radio-pharmaceutical complexes


A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four hopo moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four hopo moieties is substituted at the n-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the cd22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided..
Algeta Asa
04/16/15
20150104383

Selenocysteine mediated hybrid antibody molecules


The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier.
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services
04/16/15
20150104354

Nanofluidic sensor comprising spatially separated functional sensing components


A method for making multiple single molecule receptors in a nanopore structure includes depositing a first material and a second material by a physical vapor deposition (pvd) technique onto different selected interior surfaces of a nanochannel and functionalizing a surface of the first material, the second material, or both the first and second materials with a chemical compound having at least two functional groups. The first and second materials can be the same or different and form patches having diameters of about 1 to about 100 nanometers (nm).
International Business Machines Corporation
04/16/15
20150104353

Directed surface functionalization on selected surface areas of topographical features with nanometer resolution


A method for making a single molecule receptor in a nanopore structure includes depositing a material by a physical vapor deposition (pvd) technique onto a selected interior surface of a nanochannel and functionalizing a surface of the material with a chemical compound having at least two functional groups. The material forms a patch having a diameter of about 3 to about 10,000 nanometers (nm).
International Business Machines Corporation


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         











0.6491

3799

1 - 1 - 84